MAM
JANX icon

Martingale Asset Management’s Janux Therapeutics JANX Stock Holding History

Martingale Asset Management’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$476K Sell
30,977
-7,007
-18% -$102K 0.01% 675
2026
Q1 		$528K Buy
37,984
+26,744
+238% +$367K 0.01% 623
2025
Q4 		$155K Buy
+11,240
New +$264K ﹤0.01% 756

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Martingale Asset Management's JANX Position: Q2 2026 in Review

Martingale Asset Management reduced its Janux Therapeutics (JANX) stake by 18% in Q2 2026, selling an estimated $102K and leaving 30,977 shares worth $476K. The position accounts for 0.01% of the portfolio, ranked #675.

Martingale Asset Management first reported a position in JANX in Q4 2025 and has held it in 3 quarters since. The position peaked at $528K in Q1 2026. 197 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • Martingale Asset Management held 30,977 shares of Janux Therapeutics worth $476K as of Q2 2026.
  • Martingale Asset Management sold 7,007 Janux Therapeutics shares in Q2 2026, an estimated $102K.
  • Janux Therapeutics made up 0.01% of Martingale Asset Management's portfolio in Q2 2026, its #675 holding.
  • Martingale Asset Management first reported a position in Janux Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Martingale Asset Management's Janux Therapeutics position peaked at $528K in Q1 2026.
  • 197 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Martingale Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.